Clinical trial
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of…
NCT00311376 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00311376 |
|---|---|
| Title | Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
| Lead sponsor | Allergan, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Biological, Other |
| Interventions | botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal Saline (Placebo) |
| Enrollment | 416 |
| Start date | Aug 1, 2006 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Apr 6, 2006 |
| Last update posted | Dec 4, 2015 |
| Countries | Australia, Austria, Belgium, Canada, Czechia, France, Germany, New Zealand, Poland, Russia, Slovakia, Ukraine and 2 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: